Advanced

The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia.

Larsson, Victoria; Aarsland, Dag; Ballard, Clive; Minthon, Lennart LU and Londos, Elisabet LU (2010) In International Journal of Geriatric Psychiatry 25(10). p.1030-1038
Abstract
OBJECTIVE: Two common and characteristic sleep disturbances have been described in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD); excessive daytime sleepiness and REM sleep behaviour disorder (RBD). This study is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on the sleep disturbances in DLB and PDD patients. METHODS: Patients with DLB or PDD were included in a placebo-controlled, randomised controlled study of memantine (20 mg per day) for 24 weeks. The Stavanger Sleep Questionnaire and the Epworth Sleepiness Scale were used to evaluate the effect on sleep disturbances. RESULTS: Forty two patients started treatment; 20 with... (More)
OBJECTIVE: Two common and characteristic sleep disturbances have been described in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD); excessive daytime sleepiness and REM sleep behaviour disorder (RBD). This study is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on the sleep disturbances in DLB and PDD patients. METHODS: Patients with DLB or PDD were included in a placebo-controlled, randomised controlled study of memantine (20 mg per day) for 24 weeks. The Stavanger Sleep Questionnaire and the Epworth Sleepiness Scale were used to evaluate the effect on sleep disturbances. RESULTS: Forty two patients started treatment; 20 with memantine and 22 with placebo. The primary analysis was the comparison of change between the two groups during a 24-week period, using the modified ITT population (last observation carried forward). At 24 weeks, patients treated with memantine were less physically active during sleep while patients in the placebo group worsened. Mean difference between the groups (0.5 [0.05-0.90]) was significant (p = 0.006). No significant change was observed in severity of excessive daytime sleepiness. CONCLUSIONS: Memantine decreases probable REM sleep behaviour disorder in patients with DLB and PDD. Both diagnostic groups contributed equally to the outcome. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Geriatric Psychiatry
volume
25
issue
10
pages
1030 - 1038
publisher
John Wiley and Sons Ltd
external identifiers
  • wos:000283341700012
  • pmid:20872929
  • scopus:78649409851
ISSN
1099-1166
DOI
10.1002/gps.2506
language
English
LU publication?
yes
id
c11a64f0-7c67-4af2-9acc-ecf6cbcc24ce (old id 1687800)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20872929?dopt=Abstract
date added to LUP
2010-10-07 15:44:45
date last changed
2018-07-01 04:21:54
@article{c11a64f0-7c67-4af2-9acc-ecf6cbcc24ce,
  abstract     = {OBJECTIVE: Two common and characteristic sleep disturbances have been described in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD); excessive daytime sleepiness and REM sleep behaviour disorder (RBD). This study is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on the sleep disturbances in DLB and PDD patients. METHODS: Patients with DLB or PDD were included in a placebo-controlled, randomised controlled study of memantine (20 mg per day) for 24 weeks. The Stavanger Sleep Questionnaire and the Epworth Sleepiness Scale were used to evaluate the effect on sleep disturbances. RESULTS: Forty two patients started treatment; 20 with memantine and 22 with placebo. The primary analysis was the comparison of change between the two groups during a 24-week period, using the modified ITT population (last observation carried forward). At 24 weeks, patients treated with memantine were less physically active during sleep while patients in the placebo group worsened. Mean difference between the groups (0.5 [0.05-0.90]) was significant (p = 0.006). No significant change was observed in severity of excessive daytime sleepiness. CONCLUSIONS: Memantine decreases probable REM sleep behaviour disorder in patients with DLB and PDD. Both diagnostic groups contributed equally to the outcome.},
  author       = {Larsson, Victoria and Aarsland, Dag and Ballard, Clive and Minthon, Lennart and Londos, Elisabet},
  issn         = {1099-1166},
  language     = {eng},
  number       = {10},
  pages        = {1030--1038},
  publisher    = {John Wiley and Sons Ltd},
  series       = {International Journal of Geriatric Psychiatry},
  title        = {The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia.},
  url          = {http://dx.doi.org/10.1002/gps.2506},
  volume       = {25},
  year         = {2010},
}